Leadership

Michele Holcomb has over 25 years of experience in the healthcare industry, as a scientist, strategist, and global leader of business development and R&D.  Michele brings a broad knowledge of the healthcare ecosystem, across pharmaceutical companies, payors, providers, pharmacies, and the dynamics among them.  She has worked with companies at all stages of pharmaceutical development and with companies in healthcare services.

Michele currently serves as the Executive Vice President of Strategy and Corporate Development at Cardinal Health.  She works with business leaders to develop strategy and identify opportunities for innovation and growth. Her team also leads the execution and integration of acquisitions, partnerships and divestitures.

Michele came to Cardinal Health from Teva Pharmaceuticals where she held roles in R&D and Strategy.  Her roles included Chief Operating Officer of Global R&D and Senior Vice President of Strategy, Portfolio, Search and Partnerships, and Vice President of Corporate Strategy.

Prior to Teva, Michele was a Partner in the Global Pharmaceutical Practice at McKinsey & Company, where she spent 15 years.  She served 6 of the top 10 global pharmaceutical companies, as well as high-growth biotechs and mid-cap pharmaceutical companies. 

Michele was a member of the board of naviHealth, a private, care transitions company that takes on risk to optimize clinical and financial outcomes prior to acquisition. She is a member of the Editorial Advisory Board of Pharmaceutical Executive, the World Economic Forum Strategy Officers Community, and board member for the Liberty Science Center (New Jersey) and BalletMet of Columbus, where she chairs the long-range planning committee.   Michele has lectured on healthcare strategy at Kellogg (Northwestern), Columbia and Fuqua (Duke) business schools.  

Michele is trained as a chemist, with a B.S. in Chemistry from Stanford University, a Ph.D. in Chemistry from the University of California, Berkeley, and experience as a bench chemist at Syntex Pharmaceuticals and Ciba-Geigy.